We are specifically investing:
1) how gut microbiome interacts with enteroendocrine and enteric nervous cells to manipulate gut motility and food intake
2) what is the role of gut virome in obesity and diabetes
3) how gut microbiome can contribute in drug responsiveness.
Our ultimate goal is to develop gut microbiome modulators to curve obesity and diabetes, as well as develop gut microbiome based biomarkers to predict drug efficacy and disease prevalence.